Collection: Women’s Tees & Tops
Style that speaks volumes. Our Women’s Tees & Tops collection offers a versatile range of comfortable, stylish options, including classic tees, flattering V-necks, cozy long sleeves, and more. Each piece is crafted with soft, high-quality fabrics and designed for a relaxed yet polished look—perfect for layering, lounging, or dressing up for any occasion.
More than just clothing, every item in this collection supports a meaningful cause. Profits from this collection go to Sky Foundation, a non-profit that funds pancreatic cancer research. By choosing from this collection, you’re not only embracing comfort and style but also joining the fight against pancreatic cancer.
Find your new favorite top and wear it proudly, knowing it makes a difference.
-
Women's Relaxed T-Shirt
Regular price From $37.00 USDRegular priceUnit price per -
Women's V-Neck Tee (Purple Ribbon)
Regular price $26.70 USDRegular priceUnit price per -
Women's V-Neck Tee (Supporter Jersey)
Regular price $26.70 USDRegular priceUnit price per -
Women's V-Neck Tee (Survivor Jersey)
Regular price $26.70 USDRegular priceUnit price per -
Women’s Relaxed V-Neck Tee (Embroidered Purple Ribbon)
Regular price From $40.00 USDRegular priceUnit price per -
Women’s Tank Top
Regular price $29.00 USDRegular priceUnit price per
Latest News
View all-
Phase 1/2 Trial Launches for Innovative Pancrea...
UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...
Phase 1/2 Trial Launches for Innovative Pancrea...
UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...
-
FDA Approves NALIRIFOX as First-Line Treatment ...
New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...
FDA Approves NALIRIFOX as First-Line Treatment ...
New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...
-
Immunotherapy for Pancreatic Ductal Adenocarcin...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...
Immunotherapy for Pancreatic Ductal Adenocarcin...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...
